Targeting the ERK-1/2 signalling pathway results in alloantigen-specific anergy in human T cells.
Krieger
P-M
PM
Institute of Immunology of Vienna, Department of Transplantsurgery and Internal Medicine III, University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
Säemann
M D
MD
Böhmig
G A
GA
Mühlbacher
F
F
Zlabinger
G J
GJ
D002070:Butadienes / Q000494:pharmacology; D002478:Cells, Cultured; D017635:Clonal Anergy; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology; D007519:Isoantigens / Q000276:immunology*; D008213:Lymphocyte Activation / Q000187:drug effects; D020935:MAP Kinase Signaling System / Q000276:immunology*; D019950:Mitogen-Activated Protein Kinase 1 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D009570:Nitriles / Q000494:pharmacology; D011994:Recombinant Proteins / Q000494:pharmacology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*
D002070:Butadienes; D004791:Enzyme Inhibitors; D007376:Interleukin-2; D007519:Isoantigens; D009570:Nitriles; D011994:Recombinant Proteins; C113580:U 0126; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases